Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USP Draft Medicare Formulary Sets 146 Drug Categories And Classes

This article was originally published in The Pink Sheet Daily

Executive Summary

The proposed total is greater than the number of classes desired by PBMs but falls below the threshold drug manufacturers are seeking. Medicare Part D plans following the model formulary would have to offer at least two drugs in each therapeutic category and pharmacologic class.

You may also be interested in...



Medicare Formularies Need One Of Each USP “Key Drug Type,” CMS Says

The Centers for Medicare & Medicaid Services expects Medicare prescription drug plan formularies to include at least one drug from each of U.S. Pharmacopeia's "formulary key drug types" list

Medicare Formularies Need One Of Each USP “Key Drug Type,” CMS Says

The Centers for Medicare & Medicaid Services expects Medicare prescription drug plan formularies to include at least one drug from each of U.S. Pharmacopeia's "formulary key drug types" list

USP's Finalized Model For Medicare Rx Formularies Retains 146 Drug Groups

Overall, the model guidelines resemble the version proposed by USP in August but include revisions to specific therapeutic categories and pharmacologic classes. Proton pump inhibitors are placed in a separate drug class; SSRIs/SNRIs remain off the formal chart.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel